ClinicalTrials.gg

Program

lorlatinib

Also written as “Lorlatinib”, “PF-06463922” and “Lorlatinib 50 mg”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma · Renal Insufficiency, led by 4 companies.

Furthest: phase 4, since Apr 22, 202020 company-led studies, 5 open or runningNext primary completion: Nov 30, 2028

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer173 open or runningphase 4since Apr 22, 2020Oct 16, 2013Nov 30, 2028NCT06487078
CStone Pharmaceuticals11 open or runningphase 2since Mar 17, 2022Mar 17, 2022none ahead
Hoffmann-La Roche11 open or runningphase 1since May 14, 2026May 14, 2026Aug 31, 2030phase 1 · NCT07617337
Strata Oncology10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Merck and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Oct 16, 2013.

  1. Jan 20, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03052608 · 296 enrolled · United States, Argentina, Australia and more
  2. May 17, 2017Phase 1 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03184168 · 6 enrolled · United States
  3. May 18, 2018Phase 1 study in Renal InsufficiencyPfizer · NCT03542305 · 29 enrolled · United States
  4. Sep 24, 2018Phase 1 study in NeoplasmsPfizer · NCT03726333 · 1 enrolled · United States
  5. Feb 5, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03909971 · 109 enrolled · China
  6. May 22, 2019Phase 1 study in AdultPfizer · NCT03961997 · 16 enrolled · Belgium
  7. Apr 22, 2020Phase 4 study in CarcinomaPfizer · NCT04362072 · 71 enrolled · United States, India, Italy and more
  8. Aug 21, 2020Phase 4 study in Advanced Non-Small Cell Lung CancerPfizer · NCT04541706 · 100 enrolled · India
  9. Oct 1, 2021Strata Oncology's first study: phase 2 study in NeoplasmsNew to Strata OncologyStrata Oncology · NCT05097599 · 11 enrolled · United States
  10. Nov 22, 2021Phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05144997 · 76 enrolled · United States, China, France and more
  11. Jan 24, 2022Phase 1 study in Moderate Hepatic ImpairmentPfizer · NCT05224609 · 21 enrolled · United States
  12. Mar 17, 2022CStone Pharmaceuticals's first study: phase 2 study in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerNew to CStone PharmaceuticalsCStone Pharmaceuticals · NCT05297890 · 70 enrolled · China
  13. Jun 5, 2024No phase study in ALK+ Non-Small-Cell Lung CarcinomaPfizer · NCT06487078 · 90 planned · France
  14. May 14, 2026Hoffmann-La Roche's first study: phase 1 study in ALK Positive Non-small Cell Lung CancerNew to Hoffmann-La RocheHoffmann-La Roche · NCT07617337 · 102 planned · United States, Japan

Ahead

  1. Nov 30, 2028Primary completion: no phase study in ALK+ Non-Small-Cell Lung CarcinomaPfizer · NCT06487078
  2. Oct 25, 2029Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05144997
  3. Aug 31, 2030Primary completion: phase 1 study in ALK Positive Non-small Cell Lung CancerHoffmann-La Roche · NCT07617337

TargetBeta

ALK →EML4 →read by rule
“An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), ”NCIt, by rule
“ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07617337ALK Positive Non-small Cell Lung Cancer · United States, Japan1RecruitingHoffmann-La RocheAug 31, 2030102
NCT06487078ALK+ Non-Small-Cell Lung Carcinoma · France–RecruitingPfizerNov 30, 202890
NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer · China2Active, not recruitingCStone PharmaceuticalsDec 26, 202370
NCT05224609Moderate Hepatic Impairment · United States1CompletedPfizerAug 13, 202421
NCT05144997Carcinoma, Non-Small-Cell Lung · United States, China, France and more4Active, not recruitingPfizerOct 25, 202976
NCT05097599Neoplasms · United States2TerminatedStrata OncologyJun 12, 202411
NCT04541706Advanced Non-Small Cell Lung Cancer · India4CompletedPfizerJul 20, 2022100
NCT04362072Carcinoma · United States, India, Italy and more4CompletedPfizerMay 29, 202471
NCT03961997Adult · Belgium1CompletedPfizerDec 9, 201916
NCT03909971Carcinoma, Non-Small-Cell Lung · China2CompletedPfizerAug 10, 2020109
NCT03726333Neoplasms · United States1TerminatedPfizerJul 8, 20211
NCT03542305Renal Insufficiency · United States1CompletedPfizerFeb 20, 202029
NCT03184168Carcinoma, Non-Small-Cell Lung · United States1CompletedPfizerAug 7, 20176
NCT03052608Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingPfizerMar 20, 2020296
NCT02838264Healthy · Belgium1CompletedPfizerMar 31, 201716
NCT02804399Healthy · United States1CompletedPfizerOct 201612
NCT02584634Carcinoma, Non-Small-Cell Lung · United States, Australia, Japan and more2TerminatedPfizerFeb 2, 202143
NCT02569554Healthy · Belgium1CompletedPfizerApr 201627
NCT02564562Healthy · United States1CompletedPfizerNov 20156
NCT01970865Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2CompletedPfizerMar 15, 2017364

How it is read

Names in the registry

  • “Lorlatinib”, 10 entries
  • “PF-06463922”, 8 entries
  • “lorlatinib”, 6 entries
  • “Lorlatinib 50 mg”, 1 entry
  • “Lorlatinib 75 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.